The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients

Delia Colombo, Giuseppe Banfi, Nicoletta Cassano, Alessandra Graziottin, Gino Antonio Vena, Giovanni Gualberto Fiori, Emanuela Zagni, Luca Stingeni, Sergio Chimenti, Enzo Berardesca, Giuseppe Micali, Giuseppe Albertini, Clara De Simone, Gilberto Bellia, Salvatore Amato, Fabio Ayala, Ferderico Bardazzi, Maria Grazia Bernengo, Maria Rita Bongiorno, Giovanni BorroniStefano Calvieri, Piergiacomo Calzavara Pinton, Calcedonio Cannarozzo, Serafinella Patrizia Cannavò, Angelo Cattaneo, Rossella Ceschini, Enrico Colombo, Maurizio Congedo, Francesco Cusano, Ornella De Pità, Sergio Di Nuzzo, Dario Donadio, Stefano Donelli, Raffaele Filotico, Maria Laura Flori, Maurizio Germino, Giampiero Girolomoni, Franco Kokelj, Anna Lanzoni, Giuseppe Lembo, Andrea Locatelli, Cristina Magnoni, Marco Marconi, Alberico Motolese, Manuela Papini, Aurora Parodi, Monica Pau, Ketty Peris, Stefano Piaserico, Giuseppe Ricotti, On behalf of the GENDER ATTENTION study group

Research output: Contribution to journalArticle

Abstract

Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients. Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Patients with plaque psoriasis, undergoing a new CsA administration course, or about to start it, were enrolled in the outpatient clinics of Italian dermatological centers. During the 2–6 months of study duration, patients had to note all AEs that occurred in a diary that was reviewed by the investigators at the follow-up visit. Sex hormone levels were measured within 7 days from the start date of a menstrual cycle. Results: A total of 969 adult psoriatic patients were enrolled in the study, divided into four cohorts: fertile women and corresponding age-matched men; postmenopausal women and corresponding age-matched men. A significant difference in the percentage of patients with AEs was observed between fertile and postmenopausal women, but not between women and age-matched men. AE incidence rate was about 37% higher in fertile women than in age-matched men and about 18% higher in postmenopausal women than in age-matched men, but differences were not statistically significant. Incidence rate ratio of fertile vs. postmenopausal women was 0.67, reaching statistical significance. AEs were mild or moderate in severity in the great majority of patients of all cohorts and postmenopausal women had significantly less grade 1–2 AEs compared to fertile women, but more grade 3–4 AEs. FSH levels were significantly higher in postmenopausal women reporting no AEs, and DHEA sulfate levels were about 10% higher in men with no AEs, compared to those reporting at least one AE. Cortisol levels were slightly though significantly higher in postmenopausal women with no AE. Conclusions: A better understanding of sex- and hormone-related influences on drug responses may help to improve drug safety and efficacy, by permitting one to tailor pharmacological treatments to individual subjects or defined patient cohorts. Funding: Novartis Farma S.p.A., Italy.

Original languageEnglish
Pages (from-to)1349-1363
Number of pages15
JournalAdvances in Therapy
Volume34
Issue number6
DOIs
Publication statusPublished - Jun 1 2017

Keywords

  • Adverse drug reaction
  • Cyclosporine
  • Dermatology
  • Female
  • Gender
  • Psoriasis

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients'. Together they form a unique fingerprint.

Cite this